Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer

This combined analysis of CTCs and ctDNA may offer a new approach for monitoring of disease progression and to direct therapy in patients with advanced MBC, at a time when they are coming towards the end of other treatment options.